

The Cancer Genome Atlas

Site	Ouestionn	aire

Tissue Source Site Name (TSS):
Date:

Tun			mal Specimens
Tun	nor Specimens	NOI	mai specimens
1.	Primary tumor At least 30-100 mg of tumor tissue* Matching normal control (whole blood preferred) No systemic radiation (or local radiation to the TCGA tumor site) or chemotherapy prior to resection of the TCGA tumor*	1.	Type of normal control Whole blood Extracted DNA from whole blood Buffy coat Density gradient-purified lymphocytes Non-diseased tissue, site: Other:
2.	List tumor types and estimate number of cases per tumor type:		Select which anticoagulant are used blood collection tube (these are the only acceptable anticoagulants for TCGA) □ EDTA
3.4.	Time from resection to freezing: (minutes) Method of freezing: (minutes) Snap frozen in LN2 Cryostat		☐ Heparin☐ Acid-citrate-dextrose (ACD)☐ Sodium Citrate
5.	Other:Age range of specimens collected (duration of time since tumor procurement):	3.	Noting extracted DNA, please answer the following questions: Volume of blood used to isolate cells and/or extract DNA?mL
6.	Is tissue embedded in a medium (i.e., OCT)? Yes, type: No	5.	If control is cells, what is the cell count?cell/ml How the cells are stored (temperature and freezing media)?
7.	Has a preservative been added to the tissue (i.e. RNAlater)? ☐ Yes, type: ☐ No		If the control is purified genomic DNA, which method was used to extract the DNA?
8.	In what type of vessel are the specimens stored? Cryovials Cryomolds Other:	7.	How was the genomic DNA quantified? ☐ Spec ☐ PicoGreen ☐ Other:
9.	Method of storage: □ -20°C □ -80°C □ Liquid nitrogen vapor □ Other:		How much DNA did you obtain from the extraction? Was the genomic DNA visualized by gel electrophoresis? Yes No
10.	Will a TSS pathology review be conducted from a top slide for the specimen submitted for TCGA? ———————————————————————————————————		Is the DNA predominately high molecular weight? Yes No What molecular applications have been performed on the genomic
11.	□ No How many cases have been prescreened** by TSS pathology review to date for TCGA?		DNA (sequencing, genotyping, PCR, etc.)?
Oth	ner Requirements		

PI Signature	Date

 $[\]hbox{\tt *For TCGA tumor-specific exceptions please contact your TCGA Lead Clinical Outreach Coordinator}$

^{**}The TSS is required to pre-screen each tumor and/or normal tissue and send a top slide from the frozen specimen being submitted to the BCR, along with a complete and de-identified pathology report. If the case has a diagnosis discrepancy between the TSS top slide review and pathology report, a TCGA pathology discrepancy form must be filled out and submitted with the specimen.

Tissue Source Site Overview

	rissue Source Site Overview								
Mailing Address:									
Cryoport Shipping Address:									
or yopen ompping nauncon									
Places provide contact inf	ormation for applicable porce	annol working	on the project such as PI, sub-PI, Clin	ical Poscarch Coordinators atc					
Name	Phone #	Jillel Working	Email	Role					
Name	Priorie #		Еттан	PI					
				- ''					

PI Signature

Date